Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications

Bioconjugate Chemistry

Volumn 24, Issue 2, 2013, Pages 234-241

  Steiner, Martina ^a   Gutbrodt, Katrin ^a   Krall, Nikolaus ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; INFRARED DEVICES; MOLECULES; PRODUCT DESIGN; TUMORS;

ANTIBODY-FRAGMENT; BIODISTRIBUTIONS; DELIVERY VEHICLE; DISEASE MARKERS; FUSION PROTEINS; IN-VIVO; LATE STAGE; NATURALLY OCCURRING; SMALL ORGANIC MOLECULES; TUMOR-TARGETING;

ANTIBODIES;

ANTIBODY; BINDING PROTEIN; DYE; FIBRONECTIN; FLUORESCEIN; HYBRID PROTEIN; IODINE 125; LIPOCALIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOLID TUMOR;

EID: 84874058736     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300567a     Document Type: Article

References (47)

1. Kaur, S., Venktaraman, G., Jain, M., Senapati, S., Garg, P. K., and Batra, S. K. (2012) Recent trends in antibody-based oncologic imaging Cancer Lett. 315 (2) 97-111
2. Carter, P. J. (2006) Potent antibody therapeutics by design Nat. Rev. Immunol. 6 (5) 343-57
3. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., and Zardi, L. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int. J. Cancer 102 (1) 75-85
4. Wu, A. M. and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23 (9) 1137-46
5. Roovers, R. C., van Dongen, G. A., and van Bergen en Henegouwen, P. M. (2007) Nanobodies in therapeutic applications Curr. Opin. Mol. Ther. 9 (4) 327-35
6. Tijink, B. M., Laeremans, T., Budde, M., Stigter-van Walsum, M., Dreier, T., de Haard, H. J., Leemans, C. R., and van Dongen, G. A. (2008) Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology Mol. Cancer Ther. 7 (8) 2288-97
7. Low, P. S. and Kularatne, S. A. (2009) Folate-targeted therapeutic and imaging agents for cancer Curr. Opin. Chem. Biol. 13 (3) 256-62
8. Krall, N., Scheuermann, J., and Neri, D. (2013) Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries Angew. Chem., Int. Ed. Engl. 52 (5) 1384-402
9. Sharkey, R. M., Karacay, H., Johnson, C. R., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C. H., and Goldenberg, D. M. (2009) Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma J. Nucl. Med. 50 (3) 444-53
10. Barbet, J., Bardies, M., Bourgeois, M., Chatal, J. F., Cherel, M., Davodeau, F., Faivre-Chauvet, A., Gestin, J. F., and Kraeber-Bodere, F. (2012) Radiolabeled antibodies for cancer imaging and therapy Methods Mol. Biol. 907, 681-97
11. Salaun, P. Y., Campion, L., Bournaud, C., Faivre-Chauvet, A., Vuillez, J. P., Taieb, D., Ansquer, C., Rousseau, C., Borson-Chazot, F., Bardet, S., Oudoux, A., Cariou, B., Mirallie, E., Chang, C. H., Sharkey, R. M., Goldenberg, D. M., Chatal, J. F., Barbet, J., and Kraeber-Bodere, F. (2012) Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement J. Nucl. Med. 53 (8) 1185-92
12. Cremonesi, M., Ferrari, M., Chinol, M., Stabin, M. G., Grana, C., Prisco, G., Robertson, C., Tosi, G., and Paganelli, G. (1999) Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients Eur. J. Nucl. Med. 26 (2) 110-20
13. Su, F. M., Beaumier, P., Axworthy, D., Atcher, R., and Fritzberg, A. (2005) Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212 Bi generator Nucl. Med. Biol. 32 (7) 741-7
14. Lazzeri, E., Manca, M., Molea, N., Marchetti, S., Consoli, V., Bodei, L., Bianchi, R., Chinol, M., Paganelli, G., and Mariani, G. (1999) Clinical validation of the avidin/indium-111 biotin approach for imaging infection/inflammation in orthopaedic patients Eur. J. Nucl. Med. 26 (6) 606-14
15. Gebauer, M. and Skerra, A. (2012) Anticalins small engineered binding proteins based on the lipocalin scaffold Methods Enzymol. 503, 157-88
16. Bradbury, A. R., Sidhu, S., Dubel, S., and McCafferty, J. (2011) Beyond natural antibodies: the power of in vitro display technologies Nat. Biotechnol. 29 (3) 245-54
17. Beste, G., Schmidt, F. S., Stibora, T., and Skerra, A. (1999) Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold Proc. Natl. Acad. Sci. U. S. A. 96 (5) 1898-903
18. Korndorfer, I. P., Beste, G., and Skerra, A. (2003) Crystallographic analysis of an ″anticalin″ with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region Proteins 53 (1) 121-9
19. Vopel, S., Muhlbach, H., and Skerra, A. (2005) Rational engineering of a fluorescein-binding anticalin for improved ligand affinity Biol. Chem. 386 (11) 1097-104
20. Rybak, J. N., Roesli, C., Kaspar, M., Villa, A., and Neri, D. (2007) The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases Cancer Res. 67 (22) 10948-57
21. Schliemann, C., Wiedmer, A., Pedretti, M., Szczepanowski, M., Klapper, W., and Neri, D. (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma Leuk. Res. 33 (12) 1718-22
22. Villa, A., Trachsel, E., Kaspar, M., Schliemann, C., Sommavilla, R., Rybak, J. N., Rosli, C., Borsi, L., and Neri, D. (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int. J. Cancer 122 (11) 2405-13
23. Sommavilla, R., Pasche, N., Trachsel, E., Giovannoni, L., Roesli, C., Villa, A., Neri, D., and Kaspar, M. (2010) Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12 Protein Eng. Des. Sel. 23 (8) 653-61
24. Frey, K., Schliemann, C., Schwager, K., Giavazzi, R., Johannsen, M., and Neri, D. (2010) The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma J. Urol. 184 (6) 2540-8
25. Frey, K., Zivanovic, A., Schwager, K., and Neri, D. (2011) Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation Integr. Biol. (Camb.) 3 (4) 468-78
26. Pasche, N., Woytschak, J., Wulhfard, S., Villa, A., Frey, K., and Neri, D. (2011) Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7 J. Biotechnol. 154 (1) 84-92
27. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R., and Oppermann, H. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 85 (16) 5879-83
28. Silacci, M., Brack, S., Schirru, G., Marlind, J., Ettorre, A., Merlo, A., Viti, F., and Neri, D. (2005) Design, construction, and characterization of a large synthetic human antibody phage display library Proteomics 5 (9) 2340-50
29. Zuberbuhler, K., Palumbo, A., Bacci, C., Giovannoni, L., Sommavilla, R., Kaspar, M., Trachsel, E., and Neri, D. (2009) A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells Protein Eng. Des. Sel. 22 (3) 169-74
30. Wan, S., Parrish, J. A., Anderson, R. R., and Madden, M. (1981) Transmittance of nonionizing radiation in human tissues Photochem. Photobiol. 34 (6) 679-81
31. Chmura, A. J., Orton, M. S., and Meares, C. F. (2001) Antibodies with infinite affinity Proc. Natl. Acad. Sci. U. S. A. 98 (15) 8480-4
32. Chmura, A. J., Schmidt, B. D., Corson, D. T., Traviglia, S. L., and Meares, C. F. (2002) Electrophilic chelating agents for irreversible binding of metal chelates to engineered antibodies J. Controlled Release 78 (1-3) 249-58
33. Corneillie, T. M., Whetstone, P. A., and Meares, C. F. (2006) Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting J. Inorg. Biochem. 100 (5-6) 882-90
34. Melkko, S., Dumelin, C. E., Scheuermann, J., and Neri, D. (2006) On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides Chem. Biol. 13 (2) 225-31
35. Zhang, M., Zhang, Z., Garmestani, K., Schultz, J., Axworthy, D. B., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., and Waldmann, T. A. (2003) Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts Proc. Natl. Acad. Sci. U. S. A. 100 (4) 1891-5
36. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., Seccamani, E., Siccardi, A. G., and Fazio, F. (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients Cancer Res. 51 (21) 5960-6
37. Paganelli, G., De Cicco, C., Ferrari, M. E., Carbone, G., Pagani, G., Leonardi, M. C., Cremonesi, M., Ferrari, A., Pacifici, M., Di Dia, A., De Santis, R., Galimberti, V., Luini, A., Orecchia, R., Zurrida, S., and Veronesi, U. (2010) Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin Eur. J. Nucl. Med. Mol. Imaging 37 (2) 203-11
38. Ferrari, M. E., Cremonesi, M., Di Dia, A., Botta, F., De Cicco, C., Sarnelli, A., Pedicini, P., Calabrese, M., Orecchia, R., Pedroli, G., and Paganelli, G. (2012) 3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART((R))) combined with external beam radiation therapy Eur. J. Nucl. Med. Mol. Imaging 10, 1007/s00259-012-2197-6
39. van Schaijk, F. G., Oosterwijk, E., Soede, A. C., Broekema, M., Frielink, C., McBride, W. J., Goldenberg, D. M., Corstens, F. H., and Boerman, O. C. (2005) Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody Clin. Cancer Res. 11 (19 Pt 2) 7130s-6s
40. Kraeber-Bodere, F., Salaun, P. Y., Ansquer, C., Drui, D., Mirallie, E., Faivre-Chauvet, A., Barbet, J., Goldenberg, D. M., and Chatal, J. F. (2012) Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC) Tumour Biol. 33 (3) 601-6
41. van Schaijk, F. G., Oosterwijk, E., Molkenboer-Kuenen, J. D., Soede, A. C., McBride, B. J., Goldenberg, D. M., Oyen, W. J., Corstens, F. H., and Boerman, O. C. (2005) Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models J. Nucl. Med. 46 (3) 495-501
42. Moosmayer, D., Berndorff, D., Chang, C. H., Sharkey, R. M., Rother, A., Borkowski, S., Rossi, E. A., McBride, W. J., Cardillo, T. M., Goldenberg, D. M., and Dinkelborg, L. M. (2006) Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors Clin. Cancer Res. 12 (18) 5587-95
43. Milstein, C. and Cuello, A. C. (1983) Hybrid hybridomas and their use in immunohistochemistry Nature 305 (5934) 537-40
44. Kufer, P., Lutterbuse, R., and Baeuerle, P. A. (2004) A revival of bispecific antibodies Trends Biotechnol. 22 (5) 238-44
45. Bernardes, G. J. L., Casi, G., Trussel, S., Hartmann, I., Schwager, K., Scheuermann, J., and Neri, D. (2012) A traceless vascular-targeting antibody-drug conjugate for cancer therapy Angew. Chem., Int. Ed. Engl. 51 (4) 941-4
46. Steiner, M., Hartmann, I., Perrino, E., Casi, G., Brighton, S., Jelesarov, I., Bernades, G. J. L., and Neri, D. (2012) Spacer length between antibody fold and modified cysteine shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature Chem. Sci. 10.1039/C2SC21107F
47. Casi, G., Huguenin-Dezot, N., Zuberbuhler, K., Scheuermann, J., and Neri, D. (2012) Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery J. Am. Chem. Soc. 134 (13) 5887-92